Active transepithelial transport of irinotecan (CPT-11) and its metabolites by human intestinal Caco-2 cells

Anti-Cancer Drugs

Volumn 12, Issue 5, 2001, Pages 419-432

  Yamamoto, Wataru ^a,c   Verweij, Jaap ^a   De Bruijn, Peter ^a   De Jonge, Maja J A ^a   Takano, Hiroshi ^b   Nishiyama, Masahiko ^b   Kurihara, Minoru ^c   Sparreboom, Alex ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b HIROSHIMA UNIVERSITY   (Japan)

^c SHOWA UNIVERSITY   (Japan)

Author keywords

Caco 2 cells; Intestinal transport; Irinotecan (CPT 11); Metabolism

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANION; CAMPTOTHECIN DERIVATIVE; CARRIER PROTEIN; CYCLOSPORIN A; DRUG METABOLITE; GLYCOPROTEIN P; IRINOTECAN; LANIQUIDAR; MULTIDRUG RESISTANCE PROTEIN; UNCLASSIFIED DRUG; VERAPAMIL;

ACTIVE TRANSPORT; ARTICLE; CELL MEMBRANE PERMEABILITY; CELL PROLIFERATION; CELL STRAIN CACO 2; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACCUMULATION; DRUG DIFFUSION; DRUG METABOLISM; DRUG TRANSPORT; HUMAN; HUMAN CELL; INTESTINE ABSORPTION; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BENZAZEPINES; BIOLOGICAL TRANSPORT; BIOTRANSFORMATION; CACO-2 CELLS; CAMPTOTHECIN; CELL SURVIVAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOSPORINE; HUMANS; INTESTINAL MUCOSA; P-GLYCOPROTEIN; QUINOLINES; RNA, MESSENGER; VERAPAMIL;

EID: 0034941111     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200106000-00003     Document Type: Article

References (33)

1. Therapeutic efficacy of the topoisomerase Iinhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)carbonyloxy-camptothecin against human tumor xenografts: Lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin
2. Activity of CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units
3. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11
4. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role or uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes
5. Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38) by the human UDP-glucuronosyltransferases encoded at the UGT1 locus
6. Irinotecan (CPT-11) metabolism and disposition in cancer patients
7. Factors involved in prolongation of the terminal disposition phase of SN-38: Clinical and experimental studies
8. Kinetic studies of the hydrolysis and lactonization of camptothecin and its derivatives, CPT-11 and SN-38, in aqueous solution
9. Kinetics of lactone hydrolysis in antitumor drugs of camptothecin series as studied by fluorescence spectroscopy
10. Metabolism of irinotecan (CPT-11) by human hepatic microsomes: Participation of cytochrome P450 3A and drug interactions
11. Altered irinotetcan and SN-38 disposition after intravenous and oral administration of irinotecan in mice bearing human neuroblastoma xenografts
12. Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors
13. pH-dependent uptake of irinotecan and its active metabolite, SN-38, by intestinal cells
14. Limited oral bioavallability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
15. The pharmacological role of P-glycoprotein in the intestinal epithelium
16. Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: Role of canalicular multispecitic organic anion transporter and P-glycoprotein
17. Active efflux of CPT-11 and its metabolites in human KB-derived cell lines
18. Function and expression of multidrug resistance-associated protein family in human colon adenocarcinoma cells (Caco-2)
19. Molecular targeting of mitomycin C chemotherapy
20. Role of erythrocytes and serum proteins in the kinetic profile of total 9-amino-20(S)-camptothecin in humans
21. Determination of irinotecan (CPT-11) and its active metabolite SN-38 in human plasma by reversed-phase high-performance liquid chromatography with fluorescence detection
22. Comparative studies of drug-metabolizing enzymes in dog, monkey, and human small intestines, and in Caco-2 cells
23. Evidence for different ABC-transporters in Caco-2 cells modulating drug uptake
24. MRP3, an organic anion transporter able to transport anti-cancer drugs
25. Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. Kinetics of vinblastine secretion and interaction with modulators
26. Taxol transport by human epithelial intestinal epithelial Caco-2 cells
27. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line
28. The role of giucuronidation in 7-ethyl-10-hydroxycamptothecin resistance in vitro
29. NADPH/qulnone oxidoreductase is a priority target of glioblastoma chemotherapy
30. Influence of P-glycoprotein on the transport and metabolism of indinavir in Caco-2 cells expressing cytochrome P-450 3A4
31. Pharmacokinetic modulation of irinotecan and metabolites by cyclosporin A
32. Metabolic fate of irinotecan in humans: Correlation of glucuronidation with diarrhea
33. Disposition of irinotecan and SN-38 following oral and intravenous irinotecan dosing in mice